EUVIMED · CrossrefZeitschrift
EMJ Hematology
ISSN 2053-6631 · European Medical Group
Neueste Artikel
EHA-ESMO Guidelines for the Diagnosis, Treatment, and Follow-up of Multiple Myeloma
Pneumoperitoneum, Pneumothorax, and Pneumoretroperitoneum Post Colonoscopy: A Case report and Review of Literature
Infographic: Targeted Therapeutics in CLL and MCL
Spinal Plasmacytoma Transformed Into Solitary Sacral Amyloidoma: A Case Report
What to Do When Chimeric Antigen Receptor T Cells Are Not the Most Appropriate Option in Second-Line Diffuse Large B Cell Lymphoma: Current Treatment Options for Transplant-Ineligible Patients
Review of the 28th Annual Congress of the European Hematology Association (EHA)
Transplantation Versus Gene Therapy for Sickle Cell Disease
Immunotherapy, Targeted Therapy, and Novel Approaches to Treating Lymphoma
Interview: Cynthia Dunbar
Interview: Wolfgang Miesbach
Untangling Systemic Mastocytosis: An Update on Challenges in the Diagnosis and Treatment of Myeloid Neoplasms with Systemic Mastocytosis
Untangling Systemic Mastocytosis: An Update on Challenges in the Diagnosis and Treatment of Myeloid Neoplasms with Systemic Mastocytosis
Interview: Pier Mannuccio Mannucci
RAS-ERK Pathway Genes Mutations in the Lesions from Various Tumour Loci in Multiple Myeloma
EHA 2023 Abstract Highlights
Expert Recommendations on Balancing the Risk and Mitigation Strategies of Veno-occlusive Disease When Treating Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia with Inotuzumab Ozogamicin ▼
Interview: Niamh O’Connell
Infographic: Sickle Cell Disease
Interview: Janis Abkowitz
Extension Treatment: Preventing Recurrence of Venous Thromboembolism
Steroid Toxicity in Immune Thrombocytopenia – A Series of Unfortunate Events: A Case Report
Steroid Toxicity in Immune Thrombocytopenia – A Series of Unfortunate Events: A Case Report
Real-World Impact of Pyruvate Kinase Deficiency in Children
UBA1 Non-M41 Variants Are More Aggressive than UBA1 M41 Variants in Their Haematological Manifestations
Expert Insights: Phase III Clinical Trials in Non-Transfusion-Dependent (ENERGIZE) and Transfusion-Dependent (ENERGIZE-T) α- and β-Thalassaemia
Introducing the Concept of Patient Blood Management and Haemovigilance in Government Sector Hospitals of Sindh, Pakistan
Biosimilars in Hematology: Increasing Choice, Expanding Access
Shifting Treatment Paradigms in Non-Hodgkin Lymphomas
Different Therapeutic Interventions and Mechanisms of Action of Antisickling Agents Currently in Use in Sickle Cell Disease Management
Biosimilars: Shaping the Future of Haematology
EUVIMED